Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genovis ABFRA:5GV -0.57%94 12-1 Month Momentum % is -20.37% as of Sep. 21, 2026. GuruFocus rates FRA:5GV with a GF Score™ of 94/100 and a GF Value™ of €2.31 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,352 Biotechnology companies, Genovis AB ranks worse than 51.33% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-21), Genovis AB's 12-1 Month Momentum % is -20.37%.
The industry rank for Genovis AB's 12-1 Month Momentum % or its related term are showing as below:
FRA:5GV's 12-1 Month Momentum % is ranked worse than 51.33% of 1352
companies
in the Biotechnology industry
Industry Median: -20.52
vs FRA:5GV: -20.37
Genovis AB (FRA:5GV) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Genovis AB 12-1 Month Momentum % Related Terms
FRA:5GV vs VRTX, REGN, MRNA: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, Genovis AB's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genovis AB 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genovis AB's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Genovis AB's 12-1 Month Momentum % falls into.
Genovis AB (FRA:5GV) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of -20.37% mean?
Genovis AB (FRA:5GV) has a 12-1 Month Momentum % of -20.37% as of Sep. 21, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Genovis AB and its competitors. According to the industry distribution chart, Genovis AB ranks #694 out of 1352 companies in the Biotechnology industry, placing it in the top 51.3%.
Is Genovis AB's 12-1 Month Momentum % too high?
Genovis AB's current 12-1 Month Momentum % is -20.37%. Based on the distribution chart, Genovis AB ranks #694 out of 1352 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genovis AB has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genovis AB's 12-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genovis AB ranks #694 out of 1352 companies for 12-1 Month Momentum %. This places Genovis AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Genovis AB and its competitors. Genovis AB's current 12-1 Month Momentum % is -20.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovis AB stock overvalued right now?
Based on GuruFocus' analysis, Genovis AB (FRA:5GV) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.31, compared to a current price of €1.74 — trading 24.7% below its estimated fair value. The current 12-1 Month Momentum % is -20.37%. Genovis AB's overall GF Score™ is 94/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Genovis AB (FRA:5GV), the current 12-1 Month Momentum % is -20.37% as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genovis AB (FRA:5GV) Overvalued in 2026?
Based on GuruFocus' analysis, Genovis AB stock appears to be undervalued.
The current stock price of €1.74 is trading 24.7% below its estimated GF Value™ of €2.31.
GuruFocus considers Genovis AB to be Modestly Undervalued.
Key valuation signals for FRA:5GV:
12-1 Month Momentum %: -20.37%
GF Value™: €2.31 vs. price of €1.74 (24.7% below fair value)
No single metric tells the full story. See the FRA:5GV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.
94GF Score
Get the complete analysis for FRA:5GV
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5GV has been successfully added to your 
